A comparative study: Immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer

Cancer Investigation

Volumn 20, Issue 7-8, 2002, Pages 922-931

  Mao, Yongrong ^a   Wu, Jianping ^a   Wang, Naining ^b   He, Lanxiang ^a   Wu, Chuanjing ^c   He, Qimin ^d   Skog, Sven ^d  

^a HUBEI CANCER HOSPITAL   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

^c WUHAN UNIVERSITY   (China)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytosolic thymidine kinase (TK1); Human breast cancer; Immunohistochemistry; Proliferating cell nuclear antigen (PCNA)

Indexed keywords

CYCLINE; THYMIDINE KINASE;

ACCURACY; ADULT; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOSOL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOSOL; FEMALE; FIBROADENOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMA, INTRADUCTAL; PROLIFERATING CELL NUCLEAR ANTIGEN; REFERENCE VALUES; THYMIDINE KINASE;

EID: 0036422851     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120005905     Document Type: Article

References (32)

1. Sullivan, R.P.; Mortimer, G.; Muircheartaigh, I.O. Cell proliferation in breast tumor: Analysis of histological parameters Ki67 and PCNA expression. Ir. J. Med. Sci. 1993, 162, 343-347.
2. Schwartz, G.F.; Schwarting, R.; Rabindranauth, P.; Finkel, G.C. Clinical application of serum and tissue markers in malignant disease: Breast cancer as the paradigm. Clin. Chem. 1993, 39, 2401-2412.
3. Keshgegian, A.A.; Cnaan, A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am. J. Clin. Pathol. 1995, 104, 42-49.
4. Haerslev, T.; Jacobsen, G.K.; Zedeler, K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res. Treat. 1996, 37, 101-113.
5. Landberg, G.; Roos, G. The cell cycle in breast cancer. APMIS 1997, 105, 575-589.
6. van Dierendonck, J.H.; Wijsman, J.H.; Keijzer, R.; vande Velde, C.J.; Cornelisse, C.J. Cell-Cycle-Related Staining Patterns of Anti-proliferating Cell Nuclear Antigen Monoclonal Antibodies. Comparison with BrdUrd Labeling and Ki-67 Staining. Am. J. Pathol. 1991, 138, 1165-1172.
7. Uporov, A.V.; Tsyrlina, E.V.; Pozharisskii, K.M. Immunohistochemical study of the proliferation of breast cancer cells based on the expression of proliferating cell nuclear antigen. Vopr. Onkol. 1998, 44, 49-53.
8. Agarwal, S.; Jain, R.; Rusia, U.; Gupta, R.L. Proliferating cell nuclear antigen immunostaining in breast carcinoma and its relationship to clinical and pathological variables. Indian J. Pathol. Microbiol. 1997, 40, 11-16.
9. Moriki, T.; Takahashi, T.; Kataoka, H.; Hiroi, M.; Yamane, T.; Hara, H. Proliferation marker MIB-1 correlates well with proliferative activity evaluated BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, P53, c-erbB-2 and estrogen receptor status. Pathol. Int. 1996, 46, 953-961.
10. Chu, J.S.; Huang, C.S.; Chang, K.J. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan. Cancer Lett. 1998, 25, 145-152.
11. Niewiadomska, H.; Jeziorski, A.; Olborski, B. The expression of the proliferating antigen Ki67, PCNA and products of suppressor gene p53 in primary invasive ductal breast carcinoma. J. Exp. Clin. Cancer Res. 1998, 17, 503-510.
12. Kid, S.; Leung, W.C.; Kaplan, A. Distinctive molecular form of thymidine kinase in mitochondria of normal and bromodeoxyuridine resistant HeLa cells. Eur. J. Biochem. 1973, 39, 43-48.
13. Kid, S. Thymidine kinase. Microbiol. Sci. 1985, 2, 369-375.
14. Sherley, J.L.; Kelly, T.J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem. 1988, 263, 8350-8358.
15. He, Q.; Skog, S.; Tribukait, B. Cell cycle related studies on thymidine kinase and its isoenzymes in ehrlich ascites tumors. Cell Prolif. 1991, 24, 3-14.
16. Hengstschläger, M.; Knöfler, M.; Müllner, E.W.; Ogris, E.; Wintersberger, E.; Wawra, E. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J. Biol. Chem. 1994, 19, 13836-13842.
17. He, Q.; Wang, N.; Skog, S.; Ericsson, S.; Tribukait, B. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is marker for cell proliferation. Eur. J. Cell Biol. 1996, 70, 117-124.
18. Romain, S.; Spyratos, F.; Descotes, F.; Daver, A.; Rastaing-Puissant, B.; Bougnoux, P.; Colonna, M.; Bolla, M.; Matin, P.-M. Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: A retrospective multicenter study. Int. J. Cancer 2000, 87, 860-868.
19. Wang, N.; He, Q.; Skog, S.; Ericsson, S.; Tribukait, B. Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal. Cell. Pathol. 2001, 23, 11-19.
20. Wang, N.; Tribukait, B. Proliferation activity in carcinoma and intrapithetial neoplasia of the prostate as assessed by expression of thymidine kinase I and Ki-67, and by DNA cytometry. In Wang, N. (eds): Qualitative Cellular Methods in the Evaluation of Prostate Cancer. Paper VII, pp. 1-17, 2000, Täby-Tryck AB, Stockholm, 2000.
21. Frierson, H.F., Jr.; Wolber, R.A.; Berean, K.W.; Franquemont, D.W.; Gaffey, M.J.; Boyd, J.C.; Wibur, D.C. Interobserver reproducibility of the Nottingham modification of the bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am. J. Clin. Pathol. 1995, 103, 195-198.
22. Spiessl, B.; Beahrs, O.H.; Hermanek, P. UICC international union against cancer. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors; Springer-Verlag: Berlin, 1989.
23. Bravo, R, Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp. Cell Res. 1986, 163, 287-293.
24. Bronzert, D.A.; Monaco, M.E.; Pinkus, L.; Aitken, S.; Lippman, M.E. Purification and Properties of Estrogen-Responsive Cytolasmic Thymidine Kinase from Human Breast Cancer, Cancer Res. 1981, 41, 604-610.
25. , Romain, S.; Christensen, I.J.; Chinot, O.; Balslev, I.; Rose, C.; Martin, P.-M.; Thorpe, S.M. Prognostic value of cytosolic thymidine kinase activity as marker of proliferation in breast cancer. Int. J. Cancer 1995, 61, 7-12.
26. Spyratos, F.; Martin, P.M.; Hacéne, K.; Romain, S.; Andrieu, C.; Ferrero-Paüs, M.; Deytieux, S.; Doussal, V.L.; Tubiana-Hulin, M.; Brunet, M. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J. Natl. Cancer Inst. 1992, 84, 1266-1272.
27. Romain, S.; Martin, P.M.; Klijin, J.G.; van Putten, W.L.; Look, M.P.; Guirou, O.; Foekens, J.A. DNA-Synthesis enzyme activity: A biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? Int. J. Cancer 1997, 74, 156-161.
28. O'Neill, K.L.; Hoper, M.; Odling-Smee, G.W. Can thymidine kinase levels in breast tumors predict disease recurrence? J. Natl. Cancer Inst. 1992, 84, 1925-1928.
29. He, Q.; Zou, L.; Zhang, P.A.; Liu, J.T.; Skog, S.; Fonander, T. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. Int. Biol. Markers 2000, 15, 139-144.
30. Wu, J.P.; Mao, Y.R.; He, L.X.; Wang, N.; Wu, C.J.; He, Q.; Skog, S. Comparison study on the expression of cytosolic thymidine kinase and proliferating cell nuclear antigen in colorectal carcinoma. Anticancer Res. 2000, 6, 4867.
31. Simpson, J.F.; Page, D.L.; Steeg, P.S. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1995, 1, 1257-1260.
32. Zhou, Q.; Wulfkuhle, J.; Ouatas, T.; et al. Cyclin D1 overexpression in a model of human breast premalignancy: Preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. Breast Cancer Res. Treat. 2000, 59, 27-39.